Co-Authors
This is a "connection" page, showing publications co-authored by ROBERT F GAGEL and CAMILO JIMENEZ.
Connection Strength
2.220
-
Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly. Horm Metab Res. 2011 Jan; 43(1):55-61.
Score: 0.380
-
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol. 2008 Nov; 159(5):517-23.
Score: 0.325
-
Primary hyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma. J Bone Miner Res. 2005 Sep; 20(9):1562-8.
Score: 0.259
-
Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab. 2004 Aug; 89(8):4142-5.
Score: 0.245
-
Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). Growth Horm IGF Res. 2004 Jun; 14 Suppl A:S150-7.
Score: 0.243
-
A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr Relat Cancer. 2013 Dec; 20(6):809-23.
Score: 0.116
-
The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013 Nov; 98(11):E1813-9.
Score: 0.115
-
Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am. 2008 Jun; 37(2):481-96, x-xi.
Score: 0.080
-
Bone loss in patients with breast or prostate cancer. Curr Osteoporos Rep. 2007 Dec; 5(4):170-8.
Score: 0.077
-
Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab. 2006 Aug; 91(8):2851-8.
Score: 0.070
-
A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2004 Jul; 89(7):3521-6.
Score: 0.061
-
Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328.
Score: 0.046
-
Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402.
Score: 0.039
-
Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 2016 12; 26(12):1744-1751.
Score: 0.036
-
Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877.
Score: 0.036
-
Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106.
Score: 0.030
-
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42.
Score: 0.027
-
Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract. 2008 Dec; 14(9):1108-14.
Score: 0.021
-
Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26.
Score: 0.015